Future Of Lilly’s Arxxant In Doubt
This article was originally published in The Pink Sheet Daily
Executive Summary
Lilly says it is considering options for the investigational diabetic retinopathy treatment after FDA rejected the company's appeal of a recent "approvable" decision.